Active ingredient/trade name
|
Risks and adverse events
|
Human
pdC1-INH concentrates
|
|
Berinert
|
A theorical risk
of pathogen transmission is associated with all plasma products. No such
transmissions had been described. In this respect, the
product can be judged to be safe. It was speculated that long-term use of Berinert may be associated with an increased frequency of
HAE-C1-INH attacks.
|
Cinryze
|
A theorical risk
of pathogen transmission is associated with all plasma products. No such
transmissions hace thus far been described. In this
respect, the product can be judged to be safe.
|
Recombinat
human C1-INH concentrate
|
|
Ruconest
|
Several patiens
developed antibodies to rabbit antigens (from dander and hair, not from the
C1-INH); allergic reactions were observed rarely.
|
Kallikrein and
bradikinin receptor antagonist
|
|
Icatibanr/Firazyr
|
From the theorical
perspective, caution is advised in patients with ischemic heart disease,
unstable angina pectoris, and in the first weeks following a stroke.
Clinically relevant problems in this regard have not been observed to date.
|
Ecallantide/Kalbitor
|
Worth mentioning in the risk of anaphylactic
reactions (frequency according to the boxed warning in the USA full precribig information, 3,9%).
|
Attenuated
androgens
|
|
Danazol/Danatrol
Danazol/Danokrin
Danazol/Danokrine
Stanozolol/Winstrol
|
The most common adverse effects are virilization, weighy gain,
menstrual irregularities, depression/aggression, mialgia
and acné. Adverse effects such as hypercholesterolemia,
hypertension, erythrocytosis and hepatic tumors
mandate the need for regular medical checkups. Furthermore, in children,
growth disorders and premature closure of the epiphysial
cartilage are conceivable and nave not been sufficiently analyzed in clinical
sudies.
|
Antifibrinolitics
|
|
Tranexamic
acid/Cylokapron
|
The most common adverse effects are
dose-dependent gastrointestinal symptoms (nausea, vomiting and diarrea).
|